An update on the treatment of the cutaneous manifestations of systemic sclerosis: The dermatologist's point of view

Journal of Clinical and Aesthetic Dermatology

Volumn 5, Issue 7, 2012, Pages 33-43

  Vitiello, Magalys ^a   Abuchar, Adriana ^a   Santana, Néstor ^b   Dehesa, Luis ^a   Kerdel, Francisco A ^a  

^a UNIVERSITY OF MIAMI HOSPITAL   (United States)

^b HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMBRISENTAN; ANTIBIOTIC AGENT; ATORVASTATIN; BOSENTAN; CALCIUM ANTAGONIST; CORTICOSTEROID; CYCLOSPORIN A; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; METHOTREXATE; NICARDIPINE; NIFEDIPINE; NITRATE; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; PENICILLAMINE; PLACEBO; PROSTACYCLIN; SILDENAFIL; SITAXSENTAN; THROMBOXANE; UNINDEXED DRUG;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTERY RECONSTRUCTION; CALCINOSIS; CONSERVATIVE TREATMENT; COPPER METABOLISM; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG WITHDRAWAL; EARLY DIAGNOSIS; ENDOTHELIUM INJURY; EXTRACAPILLARY GLOMERULONEPHRITIS; FINGER ULCER; GASTROINTESTINAL DISEASE; GLOMERULONEPHRITIS; GOODPASTURE SYNDROME; HEPATITIS; HUMAN; HYDROCOLLOID; HYPERBARIC OXYGEN; HYPERTENSION; KIDNEY DISEASE; LIPOID NEPHROSIS; LIVER FAILURE; LIVER INJURY; LIVER TOXICITY; LOW DRUG DOSE; LUNG ALVEOLITIS; LUPUS ERYTHEMATOSUS; MICROSURGERY; MULTICENTER STUDY (TOPIC); MYASTHENIA GRAVIS; MYOSITIS; NEPHROTOXICITY; PAIN; PATIENT EDUCATION; PEMPHIGUS VULGARIS; PHOTOCHEMOTHERAPY; POLYMYOSITIS; PRURITUS; PULMONARY HYPERTENSION; PUVA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RAYNAUD PHENOMENON; REHABILITATION CARE; REVASCULARIZATION; REVIEW; SCLERODERMA; SIDE EFFECT; SKIN FIBROSIS; SKIN INFECTION; SKIN MANIFESTATION; SKINFOLD THICKNESS; SYMPATHECTOMY; SYSTEMIC SCLEROSIS; TASTE DISORDER; THROMBOCYTOPENIA; THROMBOSIS; TRANSIENT ACANTHOLYTIC DERMATOSIS; TREATMENT OUTCOME; ULCER HEALING; ZINC METABOLISM;

EID: 84866296699     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (107)

1. Generini S, Matucci Cerinic M. Raynaud's phenomenon and vascular disease in systemic sclerosis. Adv Exp Med Biol. 1999;455:93-100. (Pubitemid 32187446)
2. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol. 1988;15:202-205. (Pubitemid 18073738)
3. Krieg T, Takehara K. Skin disease: a cardinal feature of systemic sclerosis. Rheumatology. 2009;48(Suppl 3):iii14-18.
4. Raynaud M. De l'asphyxie locale et de la gangrene symetrique des extremites. These de Medicine. Paris: Rigoux Ed;1862:174.
5. Wigley FM. Clinical practice. Raynaud's phenomenon. N Engl J Med. 2002;347(13):1001-1008.
6. Browns S. Management of digital ulcers related to systemic sclerosis. Nursing Standard. February 11, 2010; 24,32,53-62.
7. Steen V, Denton CP, Pope J, et al. Digital ulcers: overt vascular disease in systemic slerosis. Rheumatology. 2009;48:iii19-iii24.
8. Schiopu E, Impens A, Phillips K. Digital ischemia in scleroderma spectrum of disease. Int J Rheumatology. 2010;2010:923743.
9. Gholam P, Sehr T, Enk A, Hartmann M. Successful treatment of systemic-sclerosis related digital ulcers with a selective endothelin type A receptor antagonist (sitaxsentan). Dermatology. 2009;219:171-173.
10. Kowal-Bielecka O, Landewé R, Avouac J, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009;68(5):620-628.
11. Galiè N, Hoeper MM, Gibbs JS, Simonneau G. Liver toxicity of sitaxentan in pulmonary arterial hypertension. Eur Respir J. 2011;37(2):475-476.
12. Herrick AL, van den Hoogen F, Gabrielli A, et al. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis Rheum. 2011;63(3):775-782.
13. Abou-Raya A, Abou-Raya S, Helmii M. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers. J Rheumatol. 2008;35:1801-1808.
14. Alan Ward W, Van Moore A. Management of finger ulcers in scleroderma. J Hand Surg. 1995;20(5):868-872.
15. Gahhos F, Ariyan S, Franzier WH. Management of sclerodermal finger ulcers. J Hand Surg Am. 1984;9(3):320-327. (Pubitemid 14113285)
16. Poole JL. Musculoskeletal rehabilitation in the person with scleroderma. Curr Opin Rheumatol. 2010;22(2):205-212.
17. Steen V, Conte C, Medsger TA Jr. Case control study of corticosteroid use prior to scleroderma renal crisis. Arthritis Rheum. 1994;37(Suppl):S360.
18. Sharada B, Kumar A, Kakker R, et al. Intravenous dexamethasone pulse therapy in diffuse systemic sclerosis. A randomized placebo-controlled study. Rheumatol Int. 1994;14:91.
19. Pai BS, Srinivas CR, Sabitha L, et al. Efficacy of dexamethasone pulse therapy in progressive systemic sclerosis. Int J Dermatol. 1995;34(10):726-728.
20. Jimenez SA, Sigal SH. A 15-year prospective study of treatment of rapidly progressive systemic sclerosis with D-penicillamine. J Rheumatol. 1991;18(10):1496-1503.
21. Medsger TA Jr, Lucas M, Wildy KS, Baker C. D-penicillamine in systemic sclerosis? Yes! Scand J Rheumatol. 2001;30(4):192-194. (Pubitemid 32762853)
22. Steen VD, Blair S, Medsger TA Jr. The toxicity of D-penicillamine in systemic sclerosis. Ann Intern Med. 1986;104(5):699-705. (Pubitemid 16114565)
23. Yung CW, Hambrick CW JR. D-penicillamine-induced pemphigus syndrome. J Am Acad Dermatol. 1982;6:317-324. (Pubitemid 12183575)
24. Torres CF, Griggs RC, Baum J, Penn AS. Penicillamine-induced myasthenia gravis in progressive systemic sclerosis. Arthritis Rheum. 1980;23(4):505-508. (Pubitemid 10149460)
25. Tsankov NK, Lazarova AZ, Vasileva SG, Obreshkova EV. Lupus erythematosus-like eruption due to D-penicillamine in progressive systemic sclerosis. Int J Dermatol. 1990;29(8):571-574. (Pubitemid 20345109)
26. Santos JC, Velasco JA. Polymyositis due to D-penicillamine in a patient with systemic sclerosis. Clin Exp Dermatol. 1991;16(1):76.
27. Zvulunov A, Grunwald MH, Avinoach I, Halevy S. Transient acantholytic dermatosis (Grover's disease) in a patient with progressive systemic sclerosis treated with D-penicillamine. Int J Dermatol. 1997;36(6):476-477. (Pubitemid 27319644)
28. Nishikai M, Funatsu Y, Homma M. Monoclonal gammopathy penicillamine-induced polymyositis and systemic sclerosis. Arch Dermatol. 1974;110(2):253-255.
29. Alekperov RT, Avdeev SN, Kotovskaia MA. Obliterating bronchiolitis induced by D-penicillamine in the female patient with systemic scleroderma. Ter Arkh. 2004;76(3):74-76.
30. Derk CT, Jimenez SA. Goodpasture-like syndrome induced by D-penicillamine in a patient with systemic sclerosis: report and review of the literature. J Rheumatol. 2003;30(7):1616-1620. (Pubitemid 36835465)
31. Kitazawa K, Ohseto Y, Kawazumi H, et al. D-penicillamine-induced lipoid nephrosis in a patient with scleroderma. Ryumachi. 1982;22(5):397-403.
32. Kyndt X, Ducq P, Bridoux F, et al. Extracapillary glomerulonephritis with anti-myeloperoxidase antibodies in 2 patients with systemic scleroderma treated with penicillamine D. Presse Med. 1999;28(2):67-70. (Pubitemid 29046778)
33. Knudsen L, Weismann K. Taste dysfunction and changes in zinc and copper metabolism during penicillamine therapy for generalized scleroderma. Acta Med Scand. 1978;204(1-2):75-79. (Pubitemid 8406948)
34. Natsuda H, Matsui Y, Sakauchi M, et al. Progressive systemic sclerosis complicated with immune thrombocytopenia during D-penicillamine therapy. Intern Med. 1992;31(2):244-245.
35. Derk CT, Huaman G, Jimenez SA. A retrospective randomly selected cohort study of D penicillamine treatment in rapidly progressive diffuse cutaneous systemic sclerosis of recent onset. Br J Dermatol. 2008;158(5):1063-1068. (Pubitemid 351521424)
36. Clements PJ, Lachenbruch PA, Sterz M, et al. Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients. Arthritis Rheum. 1993;36(1):75-83. (Pubitemid 23048682)
37. Casoli P, Carretti C, Tumiati B. Scleroderma renal crisis as a possible complication of cyclosporin A withdrawal. Clin Rheumatol. 1994;13(1):126-128. (Pubitemid 24102632)
38. Zachariae H, Hansen HE, Olsen TS. Hemolytic uremic syndrome in a patient with systemic sclerosis treated with cyclosporin A. Acta Derm Venereol. 1992;72(4):307-309.
39. Roch B, Wollina U, Schroeder HE. Long-term cyclosporin A in systemic sclerosis. J Eur Acad Dermatol Venereol. 2004;18(2):235-236.
40. Das SN, Alam MR, Islam N, et al. Placebo controlled trial of methotrexate in systemic sclerosis. Mymensingh Med J. 2005;14(2):228.
41. Pope JE, Bellamy N, Seibold JR, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum. 2001;44(6):1351-1358. (Pubitemid 32537533)
42. van den Hoogen FH, Boerbooms AM, Swaak AJ, et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol. 1996;35(4):364-372.
43. Low AH, Lee P. Indirect evidence for the efficacy of methotrexate in diffuse systemic sclerosis. J Rheumatol. 2008;35(11):2286.
44. Scheja A, Hesselstrand R, Wildt M, Akesson A. Relapse of skin thickening after discontinuation or decrease of azathioprine therapy in a patient with diffuse cutaneous systemic sclerosis. Rheumatology (Oxford). 2007;46(12):1862-1863. Epub 2007 Oct 30.
45. Clements P, Lachenbruch P, Furst D, Paulus H. The course of skin involvement in systemic sclerosis over three years in a trial of chlorambucil versus placebo. Arthritis Rheum. 1993;36(11):1575-1579. (Pubitemid 23327756)
46. Furst DE, Clements PJ, Hillis S, et al. Immunosuppression with chlorambucil, versus placebo, for scleroderma. Results of a three-year, parallel, randomized, double-blind study. Arthritis Rheum. 1989;32(5):584-593. (Pubitemid 19146699)
47. Casas JA, Subauste CP, Alarcón GS. A new promising treatment in systemic sclerosis: 5-fluorouracil. Ann Rheum Dis. 1987;46(10):763-767. (Pubitemid 17140299)
48. Tashkin DP, Elashoff R, Clements PJ, et al. Scleroderma Lung Study Research Group. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med. 2007;176(10):1026-1034. (Pubitemid 350127847)
49. Gillery P, Serpier H, Polette M, et al. Gamma-interferon inhibits extracellular matrix synthesis and remodeling in collagen lattice cultures of normal and scleroderma skin fibroblasts. Eur J Cell Biol. 1992;57(2):244-253.
50. Hein R, Behr J, Hündgen M, et al.Treatment of systemic sclerosis with gamma-interferon. Br J Dermatol. 1992 May;126(5):496-501.
51. Grassegger A, Schuler G, Hessenberger G, et al. Interferon-gamma in the treatment of systemic sclerosis: a randomized controlled multicentre trial. Br J Dermatol. 1998;139(4):639-648. (Pubitemid 28474310)
52. Hunzelmann N, Anders S, Fierlbeck G, et al. Systemic scleroderma. Multicenter trial of 1 year of treatment with recombinant interferon gamma. Arch Dermatol. 1997;133(5):609-613. (Pubitemid 27214970)
53. Polisson RP, Gilkeson GS, Pyun EH, et al. A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis: effects on cutaneous fibrosis and interleukin 2 receptor levels. J Rheumatol. 1996;23(4):654-658. (Pubitemid 26132850)
54. Black CM, Silman AJ, Herrick AI, et al. Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 1999;42(2):299-305. (Pubitemid 29072847)
55. Hulshof MM, Bouwes Bavinck JN, Bergman W, et al. Double-blind, placebo-controlled study of oral calcitriol for the treatment of localized and systemic scleroderma. J Am Acad Dermatol. 2000;43(6):1017-1023.
56. Ikeda T, Uede K, Hashizume H, Furukawa F. The Vitamin A derivative etretinate improves skin sclerosis in patients with systemic sclerosis. Dermatol Sci. 2004;34(1):62-66. (Pubitemid 38134476)
57. Maurice PD, Bunker CB, Dowd PM. Isotretinoin in the treatment of systemic sclerosis. Br J Dermatol. 1989;121(3):367-374. (Pubitemid 19222149)
58. Mizutani H, Yoshida T, Nouchi N, Hamanaka H, Shimizu M. Topical tocoretinate improved hypertrophic scar, skin sclerosis in systemic sclerosis and morphea. J Dermatol. 1999;26(1):11-17. (Pubitemid 29088827)
59. Seibold JR, Clements PJ, Furst DE, et al. Safety and pharmacokinetics of recombinant human relaxin in systemic sclerosis. J Rheumatol. 1998;25(2):302-307. (Pubitemid 28088259)
60. Seibold JR, Korn JH, Simms R, et al. Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2000;132(11):871-879. (Pubitemid 30346849)
61. Seibold JR. Relaxins: lessons and limitations. Curr Rheumatol Rep. 2002;4(4):275-276.
62. Khanna D, Clements PJ, Furst DE, et al with the Relaxin Investigators and the Scleroderma Clinical Trials Consortium. Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2009;60(4):1102-1111.
63. Levy Y, Sherer Y, Langevitz P, et al. Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin - a preliminary report. Clin Rheumatol. 2000;19(3):207-211. (Pubitemid 30341255)
64. Levy Y, Amital H, Langevitz P, et al. Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study. Arthritis Rheum. 2004;50(3):1005-1007. (Pubitemid 38326203)
65. Rook AH, Freundlich B, Jegasothy BV, et al. Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multicenter trial. Arch Dermatol. 1992;128(3):337-346.
66. Knobler RM, French LE, Kim Y, et al. Systemic Sclerosis Study Group. A randomized, double-blind, placebo-controlled trial of photopheresis in systemic sclerosis. J Am Acad Dermatol. 2006;54(5):793-799.
67. Zachariae H, Bjerring P, Heickendorff L, Møller B, Wallevik K. Photopheresis and systemic sclerosis. Arch Dermatol. 1992;128(12):1651-1653.
68. Paye M, Read D, Nusgens B, Lapiere CM. Factor XIII in scleroderma: in vitro studies. Br J Dermatol. 1990;122(3):371-382. (Pubitemid 20122724)
69. Guillevin L, Euller-Ziegler L, Chouvet B, et al. Treatment of systemic scleroderma with factor XIII in 86 patients, with long-term follow-up. Presse Med. 1985;14(46):2327-2329. (Pubitemid 16197236)
70. Phumethum V, Jamal S, Johnson SR. Biologic therapy for systemic sclerosis: a systematic review. J Rheumatol. 2011;38(2):289-296.
71. Distler JH, Jüngel A, Huber LC, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum. 2007;56(1):311-322. (Pubitemid 46106205)
72. Soria A, Cario-André M, Lepreux S, et al. The effect of imatinib (Glivec) on scleroderma and normal dermal fibroblasts: a preclinical study. Dermatology. 2008;216(2):109-117. (Pubitemid 351158574)
73. Khanna D, Saggar R, Mayes MD, et al. Open-label pilot trial of imatinib mesylate (Gleevec) in the treatment of systemic sclerosis- associated active interstitial lung disease (SSc-ILD). Arthritis Rheum. 2011 Jul 18. doi: 10.1002/art.30548.
74. Tamaki Z, Asano Y, Hatano M, et al. Efficacy of low-dose imatinib mesylate for cutaneous involvement in systemic sclerosis: a preliminary report of three cases. Mod Rheumatol. 2011 Jun 3.
75. Pope J, McBain D, Petrlich L, et al. Imatinib in active diffuse systemic sclerosis: a single site trial. Arthritis Rheum. 2011 Jul 18. doi: 10.1002/art.30549.
76. Spiera RF, Gordon JK, Mersten JN, et al. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis. 2011;70(6):1003-1009. Epub 2011 Mar.
77. Bosello S, De Luca G, Tolusso B, et al. B cells in systemic sclerosis: a possible target for therapy. Autoimmun Rev. 2011 Apr 22.
78. Leask A. B cell block: is rituximab a new possible treatment for systemic sclerosis? J Cell Commun Signal. 2010;4(4):201-202. Epub 2010 Nov 20.
79. Panopoulos ST, Sfikakis PP. Biological treatments and connective tissue disease associated interstitial lung disease. Curr Opin Pulm Med. 2011 May 19.
80. Melone CP Jr, McLoughlin JC, Beldner S. Surgical management of the hand in scleroderma. Curr Opin Rheumatol. 1999;11(6):514-520. (Pubitemid 29506180)
81. Sakakibara N, Sugano S, Morita A. Ultrastructural changes induced in cutaneous collagen by ultraviolet-A1 and psoralen plus ultraviolet A therapy in systemic sclerosis. J Dermatol. 2008;35(2):63-69. (Pubitemid 351229595)
82. de Souza RB, Macedo AR, Kuruma KA, Macedo PA, Borges CT. Pentoxyphylline in association with vitamin E reduces cutaneous fibrosis in systemic sclerosis. Clin Rheumatol. 2009;28(10):1207-1212.
83. Barr PO, Enfors W, Eriksson G. Hyperbaric oxygen therapy in dermatology. Br J Dermatol. 1972;86(6):631-635.
84. Zarafonetis CJ, Dabich L, Skovronski JJ, et al. Retrospective studies in scleroderma: skin response to potassium para-aminobenzoate therapy. Clin Exp Rheumatol. 1988;6(3):261-268.
85. Clegg DO, Reading JC, Mayes MD, et al. Comparison of aminobenzoate potassium and placebo in the treatment of scleroderma. J Rheumatol. 1994;21(1):105-110. (Pubitemid 24044928)
86. Nash RA, McSweeney PA, Nelson JL, et al. Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis. Arthritis Rheum. 2006;54(6):1982-1986. (Pubitemid 43877948)
87. Gruber BL, Kaufman LD. A double-blind randomized controlled trial of ketotifen versus placebo in early diffuse scleroderma. Arthritis Rheum. 1991;34(3):362-366.
88. Herrick AL, Gush RJ, Tully M, Jayson MI. A controlled trial of the effect of topical glyceryl trinitrate on skin blood flow and skin elasticity in scleroderma. Ann Rheum Dis. 1994;53(3):212. (Pubitemid 24123880)
89. Paolino JS, Kaplan D, Lazarus R, Emmanuel G, Diamond HS. Phenformin and ethyloestrenol in scleroderma. Lancet. 1972;1(7758):1023.
90. Stavá Z, Kobíková M. Salazopyrin in the treatment of scleroderma. Br J Dermatol. 1977;96(5):541-544. (Pubitemid 8116972)
91. Denton CP, Engelhart M, Tvede N, et al. An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2009;68(9):1433-1439.
92. Schanz S, Ulmer A, Fierlbeck G. Response of dystrophic calcification to intravenous immunoglobulin. Arch Dermatol. 2008;144(5):585-587. (Pubitemid 351724418)
93. Sparsa A, Lesaux N, Kessler E et al. Treatment os cutaneous calcinosis in CREST syndrome by extracorporeal shock wave lithotripsy. J Am Acad Dermatol. 2005;53:S263-S265. (Pubitemid 41443485)
94. Robertson LP, Marshall RW, Hickling P. Treatment of cutaneous calcinosis in limited systemic sclerosis with minocycline. Ann Rheum Dis. 2003;62:267-269. (Pubitemid 36238096)
95. Berger RG, Featherstone GL, Raasch RH, et al. Treatment of calcinosis universalis with low-dose warfarin. Am J Med. 1987;83(1):72-76. (Pubitemid 18099029)
96. Yoshida S, Torikai K. The effects of warfarin on calcinosis in a patient with systemic sclerosis. J Rheumatol. 1993;20(7):1233-1235. (Pubitemid 23278185)
97. Cukierman T, Elinav E, Korem M, Chajek-Shaul T. Low dose warfarin treatment for calcinosis in patients with systemic sclerosis. Ann Rheum Dis. 2004;63:1341-1343. (Pubitemid 39273520)
98. Ichiki Y, Akiyama T, Shimozawa N, et al. An extremely severe case of cutaneous calcinosis with juvenile dematomuositis, and successful treatment with diltiazem. Br J Dermatol. 2001;144:894-897. (Pubitemid 32374801)
99. Vayssairat M, Hidouche D, Abdoucheli-Baudot N, Gaitz JP. Clinical significance of subcutaneous calcinosis in patients with systemic sclerosis. Does diltiazem induce its regression? Ann Rheum Dis. 1998;57:252-254. (Pubitemid 28323269)
100. Sharma NL, Mahajan VK, Ranjan N, et al. Systemic sclerosis sine scleroderma and calcinosis cutis: report of a rare case. Clin Rheumatol. 2010;29:215-219.
101. Kalajian AH, Perryman JH, Callen JP. Intravenous immunoglobulin therapy for dystrophic calcinosis cutis: unreliable in our hands. Arch Dermatol. 2009;145(3):334.
102. Belloli L, Ughi N, Massarotti M, et al. Role of Fetuin-A in Systemic Sclerosis-associated Calcinosis. J Rheumatol. 2010;37(12):2638-2639.
103. Grases F, Perello J, Isern B, Prieto RM. Study of a myo-hexaphoaphate- based cream to prevent dystrophic calcinosis cutis. Br J Dermatol. 2005;152:1022-1025. (Pubitemid 40704946)
104. Chan AY, Li E. Electric shock wave lithotripsy (ESWL) as a pain control measure in dermatomyositis with calcinosis cutis-old method, new discovery. Clin Rheumatol. 2005;24:172-173. (Pubitemid 40552974)
105. Chamberlain AJ, Walker NPJ. Successful palliation and significant remission of cutaneous calcinosis in CREST syndrome with carbon dioxide laser. Dermatol Surg. 2003;29:968-970. (Pubitemid 37087457)
106. Bottomley WW, Goodfield M, Sheehan-Dare RA. Digital calcification in systemic sclerosis: effective treatment with good tissue preservation using the carbon dioxide laser. Br J Dermatol. 1996;135:302-304. (Pubitemid 26252985)
107. Saddic N, Miller JJ, Miller OF, Clarke JT. Surgical debridement of painful fingertip calcinosis cutis in CREST syndrome. Arch Dermatol. 2009;145(2):212-213.